EVC siRNA (Human)
Référence MBS828633-30nmol
Conditionnement : 30nmol
Marque : MyBiosource
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
EVC siRNA – Ellis-Van Creveld Syndrome Protein Isoform 2 (Human)
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS828633MBS828633 is an siRNA targeting EVC. Also known as EVC siRNA (Human). Reactive in Human. Host: Synthetic. siRNA to inhibit EVC expression using RNA interference More details
Product Overview
Online Datasheet in PDFProduct Name
EVC, siRNA
Full Product Name
EVC siRNA (Human)
Product Gene Name
EVC sirna
Product Synonym Names
Ellis-van Creveld syndrome protein; DWF-1
Host
Synthetic
Species Reactivity
Human
Form/Format
Lyophilized powder
Purity/Purification
> 97%
Specificity
EVC siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Molecular Weight
111,990 Da
OMIM
193530
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human EVC gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Applications Tested/Suitable for EVC sirna
RNA Interference (RNAi)
Other Notes
Small volumes of EVC sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Additional Details
NCBI/Uniprot data below describe general gene information for EVC. It may not necessarily be applicable to this product.
UniProt Primary Accession #
UniProt Related Accession #
GenBank Nucleotide #
NCBI Official Full Name
ellis-van Creveld syndrome protein isoform 2
NCBI Official Synonym Full Names
Ellis van Creveld protein
NCBI Official Symbol
EVC
NCBI Official Synonym Symbols
EVC1; EVCL; DWF-1
UniProt Protein Name
Ellis-van Creveld syndrome protein
UniProt Synonym Protein Names
DWF-1
Protein Family
Ellis-van Creveld syndrome protein
UniProt Gene Name
EVC
UniProt Entry Name
EVC_HUMAN
NCBI Protein Information
ellis-van Creveld syndrome protein
NCBI Summary for EVC
This gene encodes a protein containing a leucine zipper and a transmembrane domain. This gene has been implicated in both Ellis-van Creveld syndrome (EvC) and Weyers acrodental dysostosis. [provided by RefSeq, Jul 2008]
UniProt Comments for EVC
EVC: Acts as a positive mediator of Hedgehog signaling indispensable for normal endochondral growth and skeletal development. Defects in EVC are a cause of Ellis-van Creveld syndrome (EVC); also known as chondroectodermal dysplasia. EVC is an autosomal recessive disorder characterized by the clinical tetrad of chondrodystrophy, polydactyly, ectodermal dysplasia and cardiac anomalies. Patients manifest short-limb dwarfism, short ribs, postaxial polydactyly and dysplastic nails and teeth. Congenital heart defects, most commonly an atrioventricular septal defect, are observed in 60% of affected individuals. Defects in EVC are a cause of acrofacial dysostosis Weyers type (WAD); also known as Curry-Hall syndrome. Acrofacial dysostoses are a heterogeneous group of disorders combining limb defects with facial abnormalities. WAD is an autosomal dominant disorder characterized by dysplastic nails, postaxial polydactyly, acrofacial dysostosis, short limbs and short stature. The phenotype is milder than Ellis-van Creveld syndrome.
Protein type: Membrane protein, integral
Chromosomal Location of Human Ortholog: 4p16
Cellular Component: cytoplasm; integral to membrane; cilium
Biological Process: smoothened signaling pathway; muscle development; cartilage development; positive regulation of smoothened signaling pathway; skeletal development
Disease: Weyers Acrofacial Dysostosis; Ellis-van Creveld Syndrome
Show more Protein type: Membrane protein, integral
Chromosomal Location of Human Ortholog: 4p16
Cellular Component: cytoplasm; integral to membrane; cilium
Biological Process: smoothened signaling pathway; muscle development; cartilage development; positive regulation of smoothened signaling pathway; skeletal development
Disease: Weyers Acrofacial Dysostosis; Ellis-van Creveld Syndrome
Research Articles on EVC
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with EVC sirna
| Reference Product | PubMed Publications |
|---|---|
| EVC2 sirna | >40 publications with EVC and EVC2 |
| DYNC2H1 sirna | >3 publications with EVC and DYNC2H1 |
| IFT80 sirna | >2 publications with EVC and IFT80 |
| MSX1 sirna | >2 publications with EVC and MSX1 |
| CRMP1 sirna | >2 publications with EVC and CRMP1 |
| HMX1 sirna | >1 publications with EVC and HMX1 |
Pathways associated with EVC sirna
| Products by Pathway | Pathway Diagram |
|---|---|
| Activation Of SMO Pathway antibodies | Activation Of SMO Pathway Diagram |
| Hedgehog 'on' State Pathway antibodies | Hedgehog 'on' State Pathway Diagram |
| Signal Transduction Pathway antibodies | Signal Transduction Pathway Diagram |
| Signaling By Hedgehog Pathway antibodies | Signaling By Hedgehog Pathway Diagram |
Diseases associated with EVC sirna
| Disease Name | Pubmed Publications |
|---|---|
| Ellis-Van Creveld Syndrome Antibodies | >89 publications with EVC and Ellis-Van Creveld Syndrome |
| Congenital Abnormalities Antibodies | >76 publications with EVC and Congenital Abnormalities |
| Heart Defects, Congenital Antibodies | >19 publications with EVC and Heart Defects, Congenital |
| Nervous System Diseases Antibodies | >12 publications with EVC and Nervous System Diseases |
| Disease Models, Animal Antibodies | >12 publications with EVC and Disease Models, Animal |
| Hypertension Antibodies | >8 publications with EVC and Hypertension |
| Lung Diseases Antibodies | >8 publications with EVC and Lung Diseases |
| Liver Diseases Antibodies | >5 publications with EVC and Liver Diseases |
| Inflammation Antibodies | >5 publications with EVC and Inflammation |
| Weyers acrofacial dysostosis Antibodies | >5 publications with EVC and Weyers acrofacial dysostosis |
Organs/Tissues associated with EVC sirna
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Heart Antibodies | >45 publications with EVC and Heart |
| Brain Antibodies | >22 publications with EVC and Brain |
| Eye Antibodies | >20 publications with EVC and Eye |
| Bone Antibodies | >20 publications with EVC and Bone |
| Lung Antibodies | >9 publications with EVC and Lung |
| Kidney Antibodies | >5 publications with EVC and Kidney |
| Connective Tissue Antibodies | >4 publications with EVC and Connective Tissue |
| Liver Antibodies | >4 publications with EVC and Liver |
| Muscle Antibodies | >4 publications with EVC and Muscle |
| Skin Antibodies | >4 publications with EVC and Skin |